Adagene to Present at Investor and Scientific Conferences in September

Provided By GlobeNewswire

Last update: Sep 7, 2023

– Adagene’s CEO, Dr. Peter Luo, participating in SITC webinar on September 22 focused on essential role of Treg depletion for anti-CTLA-4 therapies –

SAN DIEGO and SUZHOU, China, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced the company’s participation in several upcoming investor and scientific conferences.